Patient characteristics
| . | ICIs . | No-ICIs . | P value . |
|---|---|---|---|
| Patients, n (%) | 71 (48.3) | 76 (51.7) | |
| Median age at alloBMT (IQR), y | 32 (26-40) | 36 (28-45) | P = .2 |
| Sex, n (%) | P = .8 | ||
| Male | 39 (55) | 40 (53) | |
| Female | 32 (45) | 36 (47) | |
| Median prior treatments, n (range) | 3 (2-13) | 3 (1-7) | P = .4 |
| ICI as the last therapy before, n (%) | 47 (66.2) | N/A | |
| Median time from ICI to alloBMT (IQR), d | 61 (43-145) | N/A | |
| Ann Arbor stage at diagnosis, n (%) | P = .2 | ||
| Stage I-II | 28 (39%) | 38 (50%) | |
| Stage III-IV | 43 (61%) | 38 (50%) | |
| Prior ASCT | 12 (17%) | 27 (35%) | |
| Pre-alloBMT remission status, n (%) | P = .02 | ||
| CR | 32 (45%) | 41 (54%) | |
| Partial remission | 37 (52%) | 22 (29%) | |
| Stable disease | 2 (3%) | 13 (17%) |
| . | ICIs . | No-ICIs . | P value . |
|---|---|---|---|
| Patients, n (%) | 71 (48.3) | 76 (51.7) | |
| Median age at alloBMT (IQR), y | 32 (26-40) | 36 (28-45) | P = .2 |
| Sex, n (%) | P = .8 | ||
| Male | 39 (55) | 40 (53) | |
| Female | 32 (45) | 36 (47) | |
| Median prior treatments, n (range) | 3 (2-13) | 3 (1-7) | P = .4 |
| ICI as the last therapy before, n (%) | 47 (66.2) | N/A | |
| Median time from ICI to alloBMT (IQR), d | 61 (43-145) | N/A | |
| Ann Arbor stage at diagnosis, n (%) | P = .2 | ||
| Stage I-II | 28 (39%) | 38 (50%) | |
| Stage III-IV | 43 (61%) | 38 (50%) | |
| Prior ASCT | 12 (17%) | 27 (35%) | |
| Pre-alloBMT remission status, n (%) | P = .02 | ||
| CR | 32 (45%) | 41 (54%) | |
| Partial remission | 37 (52%) | 22 (29%) | |
| Stable disease | 2 (3%) | 13 (17%) |
IQR, interquartile range; N/A, not applicable.